Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hedgehog Proteins | 9 | 2022 | 45 | 1.540 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2021 | 121 | 1.320 |
Why?
|
| High-Throughput Screening Assays | 4 | 2021 | 63 | 1.270 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2017 | 109 | 0.940 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2022 | 155 | 0.910 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2021 | 22 | 0.800 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 756 | 0.790 |
Why?
|
| Heterocyclic Compounds, 2-Ring | 1 | 2017 | 3 | 0.640 |
Why?
|
| Nuclear Localization Signals | 1 | 2017 | 14 | 0.630 |
Why?
|
| Thiazoles | 1 | 2017 | 71 | 0.610 |
Why?
|
| Polydactyly | 1 | 2017 | 1 | 0.610 |
Why?
|
| Cyclohexylamines | 1 | 2017 | 12 | 0.610 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2017 | 40 | 0.610 |
Why?
|
| Pyridines | 1 | 2017 | 113 | 0.600 |
Why?
|
| Thiophenes | 1 | 2017 | 31 | 0.590 |
Why?
|
| Pyrimidines | 1 | 2017 | 112 | 0.590 |
Why?
|
| Drug Discovery | 1 | 2017 | 77 | 0.580 |
Why?
|
| Photochemical Processes | 1 | 2014 | 17 | 0.520 |
Why?
|
| Ethanol | 4 | 2022 | 188 | 0.520 |
Why?
|
| Molecular Probes | 1 | 2014 | 23 | 0.520 |
Why?
|
| Biomimetic Materials | 1 | 2014 | 23 | 0.510 |
Why?
|
| Lipid Metabolism | 1 | 2014 | 109 | 0.490 |
Why?
|
| Cell Proliferation | 7 | 2023 | 1149 | 0.480 |
Why?
|
| Quinazolines | 1 | 2013 | 31 | 0.460 |
Why?
|
| Signal Transduction | 8 | 2019 | 1802 | 0.430 |
Why?
|
| Neoplasms | 1 | 2021 | 1033 | 0.400 |
Why?
|
| Spodoptera | 1 | 2010 | 11 | 0.390 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2010 | 7 | 0.390 |
Why?
|
| Baculoviridae | 1 | 2010 | 12 | 0.390 |
Why?
|
| Cloning, Molecular | 1 | 2010 | 310 | 0.370 |
Why?
|
| Esophageal Neoplasms | 2 | 2023 | 124 | 0.360 |
Why?
|
| Enzymes | 1 | 2009 | 30 | 0.340 |
Why?
|
| Spermatozoa | 1 | 2010 | 191 | 0.340 |
Why?
|
| Biological Assay | 1 | 2009 | 56 | 0.340 |
Why?
|
| Animals | 14 | 2023 | 14307 | 0.330 |
Why?
|
| Mice | 9 | 2023 | 5668 | 0.310 |
Why?
|
| Humans | 18 | 2023 | 34853 | 0.300 |
Why?
|
| Pregnancy | 3 | 2022 | 1503 | 0.280 |
Why?
|
| Female | 13 | 2022 | 19873 | 0.270 |
Why?
|
| Cell Line, Tumor | 5 | 2023 | 2128 | 0.260 |
Why?
|
| Embryo, Nonmammalian | 2 | 2022 | 57 | 0.250 |
Why?
|
| Zebrafish | 2 | 2022 | 118 | 0.240 |
Why?
|
| Receptor, Cannabinoid, CB1 | 2 | 2020 | 40 | 0.220 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 14 | 0.220 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2022 | 15 | 0.210 |
Why?
|
| Breast Neoplasms | 3 | 2022 | 1426 | 0.210 |
Why?
|
| NF-E2-Related Factor 2 | 2 | 2023 | 73 | 0.210 |
Why?
|
| Amino Acid Sequence | 2 | 2017 | 1124 | 0.200 |
Why?
|
| Harmine | 1 | 2021 | 2 | 0.200 |
Why?
|
| Carbolines | 1 | 2021 | 13 | 0.200 |
Why?
|
| Monoamine Oxidase | 1 | 2021 | 31 | 0.200 |
Why?
|
| Rare Diseases | 1 | 2020 | 11 | 0.190 |
Why?
|
| Cell Line | 3 | 2014 | 1289 | 0.190 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 203 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 242 | 0.190 |
Why?
|
| Fibroblast Growth Factors | 1 | 2020 | 34 | 0.190 |
Why?
|
| Drug Combinations | 1 | 2020 | 89 | 0.190 |
Why?
|
| Central Nervous System Depressants | 1 | 2020 | 37 | 0.190 |
Why?
|
| Neurogenesis | 1 | 2020 | 55 | 0.180 |
Why?
|
| Zebrafish Proteins | 1 | 2020 | 45 | 0.180 |
Why?
|
| Annexin A6 | 1 | 2019 | 14 | 0.180 |
Why?
|
| Cannabinoids | 1 | 2019 | 54 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 209 | 0.170 |
Why?
|
| Phosphorylation | 2 | 2019 | 878 | 0.160 |
Why?
|
| Esophagus | 1 | 2018 | 41 | 0.160 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 43 | 0.160 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 2 | 2017 | 10 | 0.160 |
Why?
|
| Mice, SCID | 1 | 2017 | 143 | 0.150 |
Why?
|
| Molecular Weight | 1 | 2017 | 161 | 0.150 |
Why?
|
| Hand Deformities | 1 | 2017 | 2 | 0.150 |
Why?
|
| Limb Buds | 1 | 2017 | 3 | 0.150 |
Why?
|
| Thumb | 1 | 2017 | 3 | 0.150 |
Why?
|
| Extremities | 1 | 2017 | 17 | 0.150 |
Why?
|
| Caspases | 1 | 2017 | 132 | 0.150 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2017 | 23 | 0.150 |
Why?
|
| Carcinogens, Environmental | 1 | 2017 | 34 | 0.150 |
Why?
|
| Benzhydryl Compounds | 1 | 2017 | 42 | 0.150 |
Why?
|
| Phenols | 1 | 2017 | 76 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 781 | 0.140 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2017 | 146 | 0.140 |
Why?
|
| Binding Sites | 1 | 2017 | 597 | 0.140 |
Why?
|
| Protein Binding | 2 | 2017 | 913 | 0.140 |
Why?
|
| Mutation | 2 | 2017 | 1023 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 2 | 2017 | 1530 | 0.130 |
Why?
|
| Benzophenones | 1 | 2014 | 7 | 0.130 |
Why?
|
| Heparin | 1 | 2014 | 34 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2013 | 107 | 0.110 |
Why?
|
| Hepatic Stellate Cells | 1 | 2012 | 5 | 0.110 |
Why?
|
| Transcription Factors | 1 | 2017 | 653 | 0.100 |
Why?
|
| Trans-Activators | 2 | 2003 | 167 | 0.100 |
Why?
|
| Oxides | 1 | 2012 | 89 | 0.100 |
Why?
|
| Arsenicals | 1 | 2012 | 85 | 0.100 |
Why?
|
| Protein Isoforms | 1 | 2010 | 121 | 0.090 |
Why?
|
| Apoptosis | 1 | 2017 | 1317 | 0.090 |
Why?
|
| Protein Multimerization | 1 | 2010 | 97 | 0.090 |
Why?
|
| Cell Survival | 3 | 2019 | 818 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2020 | 117 | 0.090 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 255 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 485 | 0.090 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2009 | 33 | 0.090 |
Why?
|
| Protein Kinases | 1 | 2009 | 91 | 0.080 |
Why?
|
| Methyltransferases | 1 | 2009 | 56 | 0.080 |
Why?
|
| Male | 4 | 2017 | 18870 | 0.080 |
Why?
|
| Gene Expression | 3 | 2020 | 639 | 0.080 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 1490 | 0.080 |
Why?
|
| Spheroids, Cellular | 2 | 2017 | 28 | 0.080 |
Why?
|
| Coturnix | 1 | 2003 | 2 | 0.060 |
Why?
|
| Pyrimethamine | 1 | 2023 | 10 | 0.060 |
Why?
|
| Hyperplasia | 1 | 2023 | 38 | 0.060 |
Why?
|
| Nervous System | 1 | 2003 | 29 | 0.060 |
Why?
|
| Epidermal Growth Factor | 1 | 2003 | 63 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 12 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 197 | 0.050 |
Why?
|
| Nerve Growth Factor | 1 | 2002 | 25 | 0.050 |
Why?
|
| Genomics | 1 | 2022 | 201 | 0.050 |
Why?
|
| PubMed | 1 | 2020 | 4 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2017 | 480 | 0.050 |
Why?
|
| Proteins | 1 | 2003 | 352 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2020 | 9 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 423 | 0.050 |
Why?
|
| Glutamate Decarboxylase | 1 | 2020 | 17 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2020 | 27 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2020 | 125 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2003 | 562 | 0.050 |
Why?
|
| src-Family Kinases | 1 | 2020 | 42 | 0.050 |
Why?
|
| Prognosis | 1 | 2022 | 707 | 0.050 |
Why?
|
| Pyridones | 1 | 2020 | 40 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 195 | 0.040 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 122 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2019 | 164 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 178 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2022 | 775 | 0.040 |
Why?
|
| Behavior, Animal | 1 | 2020 | 304 | 0.040 |
Why?
|
| Drug Synergism | 2 | 2012 | 171 | 0.040 |
Why?
|
| Limb Deformities, Congenital | 1 | 2017 | 2 | 0.040 |
Why?
|
| Disulfiram | 1 | 2017 | 1 | 0.040 |
Why?
|
| Teratogens | 1 | 2017 | 12 | 0.040 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2017 | 20 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 901 | 0.040 |
Why?
|
| Heterozygote | 1 | 2017 | 91 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2012 | 605 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2020 | 435 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2017 | 90 | 0.040 |
Why?
|
| Cell Culture Techniques | 1 | 2017 | 136 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 105 | 0.040 |
Why?
|
| Copper | 1 | 2017 | 101 | 0.040 |
Why?
|
| Obesity | 1 | 2022 | 965 | 0.030 |
Why?
|
| Neurons | 1 | 2002 | 1130 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2017 | 306 | 0.030 |
Why?
|
| Risk Factors | 1 | 2022 | 3414 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 528 | 0.030 |
Why?
|
| Time Factors | 2 | 2012 | 1681 | 0.030 |
Why?
|
| Mitochondria | 1 | 2017 | 454 | 0.030 |
Why?
|
| Thymidylate Synthase | 1 | 2012 | 3 | 0.030 |
Why?
|
| Niacinamide | 1 | 2012 | 10 | 0.030 |
Why?
|
| Phenylurea Compounds | 1 | 2012 | 18 | 0.030 |
Why?
|
| Growth Inhibitors | 1 | 2012 | 23 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2012 | 32 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2012 | 52 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 81 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2012 | 49 | 0.030 |
Why?
|
| Cell Division | 2 | 2003 | 296 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 160 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2012 | 423 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2017 | 874 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2012 | 147 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 834 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 195 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2003 | 1152 | 0.020 |
Why?
|
| Activin Receptors, Type I | 1 | 2003 | 4 | 0.010 |
Why?
|
| Activins | 1 | 2003 | 7 | 0.010 |
Why?
|
| Nodal Protein | 1 | 2003 | 3 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 51 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 114 | 0.010 |
Why?
|
| Epithelium | 1 | 2003 | 74 | 0.010 |
Why?
|
| CHO Cells | 1 | 2003 | 107 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2003 | 170 | 0.010 |
Why?
|
| Cell Separation | 1 | 2003 | 91 | 0.010 |
Why?
|
| Cricetinae | 1 | 2003 | 217 | 0.010 |
Why?
|
| Epitopes | 1 | 2003 | 145 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2003 | 89 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2003 | 209 | 0.010 |
Why?
|
| Plasmids | 1 | 2003 | 233 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2003 | 323 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 383 | 0.010 |
Why?
|
| Ligands | 1 | 2003 | 317 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 496 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2003 | 232 | 0.010 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2002 | 32 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2003 | 166 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2003 | 392 | 0.010 |
Why?
|
| Prosencephalon | 1 | 2002 | 25 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2003 | 183 | 0.010 |
Why?
|
| Acetylcholine | 1 | 2002 | 68 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2003 | 282 | 0.010 |
Why?
|
| Cell Count | 1 | 2002 | 129 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 135 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 859 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 984 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2002 | 608 | 0.010 |
Why?
|
| Age Factors | 1 | 2002 | 1007 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2002 | 486 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2002 | 1442 | 0.010 |
Why?
|
| Adult | 1 | 2012 | 11034 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2002 | 881 | 0.010 |
Why?
|